Antipsychotic long-acting injections in clinical practice: Medication management and patient choice

British Journal of Psychiatry

Volumn 195, Issue SUPPL. 52, 2009, Pages

  Gray, Richard ^a   Spilling, Rosalyn ^a   Burgess, David ^a   Newey, Tim ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b Mental Health Service User   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL COMPETENCE; CLINICAL PRACTICE; DOCTOR PATIENT RELATION; DRUG EFFICACY; GRANULOMA; HEALTH PRACTITIONER; HUMAN; INJECTION; INJECTION SITE ABSCESS; INJECTION SITE FIBROSIS; INJECTION SITE INDURATION; INJECTION SITE NODULE; MEDICAL DECISION MAKING; NURSE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PATIENT MONITORING; PSYCHOSIS; REVIEW; RISK BENEFIT ANALYSIS; DECISION MAKING; DELAYED RELEASE FORMULATION; HEALTH PERSONNEL ATTITUDE; HUMAN RELATION; PATIENT PARTICIPATION;

ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; DECISION MAKING; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS; MEDICATION ADHERENCE; PATIENT PARTICIPATION; PROFESSIONAL-PATIENT RELATIONS; PSYCHOTIC DISORDERS;

EID: 71249109368     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.195.52.s51     Document Type: Review

References (47)

1. Care Quality Commission. Mental health services: the 2008 survey of community mental health services. CQC, 2009 (http://www.cqc.org.uk/ usingcareservices/healthcare/patientsurveys/mentalhealthservies.cfm)
2. Gray R, Wykes T, Edmonds M, Leese M, Goumay K. Effect of a medication management training package for nurses on clinical outcomes for patients with schizophrenia: cluster randomised controlled trial. Br J Psychiatry 2004; 185: 157-162 (Pubitemid 39061460)
3. Deegan PE, Drake RE. Shared decision making and medication management in the recovery process. Psychiatr Serv 2006; 57: 1636-1639
4. Walbum J, Gray R, Gournay K, Quraishi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001; 179: 300-307 (Pubitemid 32996038)
5. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003; 33: 83-89 (Pubitemid 36113403)
6. Nosé M, Barbui C, Gray R, Tansella M. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry 2003; 183: 197-206. (Pubitemid 37070173)
7. Faerden A, Nesvåg R, Marder SR. Definitions of the term 'recovered' in schizophrenia and other disorders. Psychopathology 2008; 41: 271-278
8. McEvoy JP. Functional outcomes in schizophrenia. J Clin Psychiatry 2008; 69 (suppl 3): 20-24
9. Andresen R, Oades L, Caputi P. The experience of recovery from schizophrenia: towards an empirically validated stage model. Aust N Z J Psychiatry 2003; 37: 586-594 (Pubitemid 37369247)
10. Gray R, Leese M, Bindman J, Becker T, Burti L, David A, et al. Adherence therapy for people with schizophrenia: European multicentre randomised controlled trial. Br J Psychiatry 2006; 189: 508-514 (Pubitemid 44876869)
11. Maneesakorn S, Robson D, Gournay K, Gray R. A RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand. J Clin Nurs 2008; 15: 1-11.
12. Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull 2009; 35: 336-346
13. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 2007; 58: 482-488 (Pubitemid 46640638)
14. Gray R, Rofail D, Newey T, Allen J. Service user satisfaction with antipsychotic medication. J Adv Nurs 2005; 52: 1-7.
15. Rummel-Kluge C, Schuster T, Peters S, Kissling W. Partial compliance with antipsychotic medication is common in patients with schizophrenia. Aust N Z J Psychiatry 2008; 42: 382-388 (Pubitemid 351877211)
16. Weiden PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 2007; 68 (suppl 14): 14-19
17. Gregg L, Barrowclough C, Haddock G. Reasons for increased substance use in psychosis. Clin Psychol Rev 2007; 27: 494-510. (Pubitemid 46431229)
18. Kikkert MJ, Schene AH, Koeter MW, Robson D, Born A, Helm H, et al. Medication adherence in schizophrenia: exploring patients' carers' and professionals' views. Schizophr Bull 2006; 32: 786-794 (Pubitemid 44412866)
19. Waddell L, Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry 2009; 195 (suppl 52): s43-50.
20. O'Ceallaigh S, Fahy T. Is there a role for the depot clinic in the modern management of schizophrenia? Psychiatr Bull 2001; 25: 481-484
21. Cocoman A, Murray J. Intramuscular injections: a review of best practice for mental health nurses. J Psychiatr Ment Health Nurs 2008; 15: 424-434
22. Wynaden D, Landsborough I, McGowan S, Baigmohamad Z, Finn M, Pennebaker D, et al. Best practice guidelines for the administration of intramuscular injections in the mental health setting. Int J Ment Health Nurs 2006; 15: 195-200. (Pubitemid 44186995)
23. Janssen-Cilag. Summary of Product Characteristics: Risperdal Consta 25 mg. 37.5 mg, 50 mg. eMC, 2009 (http://emc.medicines.org.uk/emc/document.aspx? documentID=9939#POSOLOGY).
24. Mclvor A, Paluzzi M, Meguid M. Intramuscular injection abscess - past lessons relearned. N Engl J Med 1991; 324: 1897-1898
25. Wink D. Discomfort after peer administered injections in a on-campus laboratory. Nurse Educat 1992; 17: 24-26
26. Chan VO, Colville J, Persaud T, Buckley O, Hamilton S, Torregglani WC. Intramuscular injections into the buttocks: are they truly intramuscular? Eur J Radiol 2006; 58: 480-484
27. Haramati N, Lorans R, Lutwin M, Kaleya RN. Injection granulomas: intramuscle or intrafat? Arch Fam Med 1994; 3: 146-148
28. Hanh K. Brush up on your injection technique. Nursing 1990; 20: 54-58
29. Engstrom J, Giglio N, Takacs S, Ellis MC, Cherwenka DI. Procedures used to prepare and administer intramuscular injections: a study of infertility nurses. J Obstet Gynecol Neonatal Nurs 2000; 29: 159-168
30. Katsma D, Smith G. Analysis of needle path during intramuscular injection. Nurs Res 1997; 46: 288-292 (Pubitemid 127457108)
31. Craven RF, Hirnle CJ. Fundamentals of Nursing: Human Health and Function, 2nd edn. Lippincott, 1996.
32. Jones JC, Day JC, Taylor JR, Thomas CS. Investigation of depot neuroleptic injection site reactions. Psychiatr Bull 1998; 22: 605-607 (Pubitemid 28454778)
33. Hay J. Complications at site of depot neuroleptics. BMJ 1995; 311: 421.
34. Gray R, Brewin E, Noak J, Wyke-Joseph J, Sonik B. A review of the literature on HIV infection: implications for research, policy and clinical practice. J Psychiatr Ment Health Nurs 2002; 9: 405-410
35. Hughes E, Gray R. HIV prevention for people with serious mental illness: a survey of mental health workers' attitudes, knowledge and practice. J Clin Nurs 2009; 18: 591-600.
36. AstraZeneca. Promoting Shared Decision Making in Mental Health. AstraZeneca, 2007 (http://www.choicementalhealth.com).
37. Rollnick P, Mason P, Butler C. Health Behavior Change: A Guide for Practitioners: 111-112 Churchill Livingstone, 1999.
38. Slade M, McCrone P, Kuipers E, Leese M, Cahill S, Parabiaghi A, et al. Use of standardised outcome measures in adult mental health services: randomised controlled trial. Br J Psychiatry 2006; 189: 330-336 (Pubitemid 44606746)
39. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276 (Pubitemid 18039085)
40. Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 1995; 166: 650-653
41. Waddell L, Taylor A. A new self-rating scale for detecting atypical or second-generation antipsychotic side-effects. J Psychopharmacol 2008; 22: 238-243 (Pubitemid 351847452)
42. Day JC, Wood G, Dewey M, Bentall RP. Liverpool University Neuroleptic Side Effect Rating Scale. Royal College of Psychiatrists, 1995 (http://www.nhshealthquality.org/mentalhealth/toolkit/lunsers.doc).
43. Gray R, Wykes T, Parr AM, Hails E, Gournay K. The use of outcome measures to evaluate the efficacy and tolerability of antipsychotic medication: a comparison of Thorn graduate and CPN practice. J Psychiatr Ment Health Nurs 2001; 8: 191-196 (Pubitemid 33692169)
44. White J, Jones M, Gray R. Health Improvement Profile. J Psychiatr Ment Health Nurs 2009; 16: 493-580
45. Henderson C, Flood C, Leese M, Thornicroft G, Sutherby K, Szmukler G. Effect of joint crisis plans on use of compulsory treatment in psychiatry: single blind randomised controlled trial. BMJ 2004; 329: 136. (Pubitemid 38951752)
46. Srebnik DS, Rutherford LT, Peto T, Russo J, Zick E, Jaffe C, et al. The content and clinical utility of psychiatric advance directives. Psychiatr Serv 2005; 56: 5, 592-598 (Pubitemid 40586844)
47. Roger MA, King L. Drawing up and administering intramuscular injections: a review of the literature. J Adv Nurs 2000; 31: 574-582